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SUMMARY
The rationale behind the use of different conditioning protocols in allotransplanted patients is given.
Standard based on Busulfan (Bu) and Cyclophosphamide (Cy) chemotherapy protocol was used for
good risk patients and those with a positive history of liver malfunction. In poor risk patients Bu and Cy
was supported by ether Etoposide (VP-16) or Thiotepa. Toxicity of the VP-16 consiting chemotherapy
was considerably higher than that of BuCy alone. This resulted in a higher transplant related mortality
in VP-16 receiving patients. In aplastic anemias (AA) in children Cy was effective in a dose of 200
mg/kg b.w. given prior transplantation. In poor risk patients with severe AA anti-thymocyte globulin
(ATG) was used. In Fanconi anemia ATG plus low dose of Cy proved to be succesful in 4 transplanted
cases.
INTRODUCTION
Conditioning of allogeneic bone marrow/blood
transplantation is based on radio/chemo-
therapy. This treatment should secure optimal
. myeloablation, cytoreduction of malignancy in
neoplastic diseases and immunosuppression
preventing host versus graft reaction.
The treatment varies in neoplastic and
non-neoplastic diseases and depends on
stage of disease (early, intermediate or
advanced) and the extent of donor recepient
disparity. In this presentation we are sharing
with you our experience in the use of chemical
conditioning.
STANDARD RISK PATIENTS WITH HEMA-
TOLOGICAL MALIGNANCIES
Busulfan (Bu) and Cyclophosphamide (Cy) is a
backbone of our procedure. In standard risk
patients with hematological malignancies the
usual dose of Bu ( 4 x 4 mg/kg b.w.) is adjusted
accordingly to the expected higher metabolic
rate in children (Regazzi et al. 1993) (4 x 5
mg/kg b.w. in age < 3 yrs) . In children and
adults cumulative dose of 200 mg/kg b.w. of Cy
is routinely given during 4 days (BuCy4). In
cases with higher risk of veno-occlusive disease
or other hepatic complications, Cy may be
administered in a cumulative dose of 120 mg/kg
b.w. in two days time (BuCy2) and Etoposied
can be omitted (toxicity) in spite of more
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advanced stage of disease (6 patients in our
group). 20 patients have already been
allografted in our institution with the use of
BuCy4. conditioning regimen. The group
consisted of 13 patients" in early and 7 in
intermediate/advanced stage of disease. In all
cases (except 1) who received BUCy4,
hematological reconstitution was observed.
Blood~ group serology confirmed complete
chimerism in all evaluable cases. Among BuCy4
patients relapse was observed in 2 out of 20
cases (time of relapse: +100, +217 d).
POOR RISK PATIENTS WITH HEMA-
TOLOGICAL MALIGNANCIES.
To this category belonged patients with
hematological malignancies in intermediate and
advanced stage or poor laboratory or clinical
prognostic factors. Among 47 patients
transplanted in our Unit 30 fulfilled criteria of
poor ris'k All of them except 7 who received
BuCy4 , as explained above) were given more
ggressive chemical conditioning. Two protocols
are actually in peration. One includes Etoposide
(VP-16), the other - Thiotepa TT), as adjuvants
to BuCy.
1. VP-16 consisting regimen.
The cumulative dose ofVP-16 ranges from 15 to
30 mg/kg b.w. , Bu is not curtailed but Cy is
given in a dose of 120 mg/kg b.w. This regimen
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was associated with considerable toxicity.
Frequency of rash and skin pigmentation as well
as elevation of serum bilirubine level was higher
in comparison to BuCy4 protocol. This toxicity
may promote accumulation of inflammatory cells
in involved tissues, hence promoting reactivity
against skin and intestine associated antigens.
Frequency of aGvHD among patients receiving
VP-16 consisting chemical conditioning was
higher than in BuCy4 group. This association
may be merely indirect. VP-16 treated patients
were in more advanced stage of disease. This is
associated with a higher cumulative dose of
chemotherapy and related to this treatment
toxicities, what in turn increases the risk of viral
infections. Altogether transplant related mortality
was higher among patients with more advanced
disease receiving VP-16 as a part of conditioning
regimen than in BuCy4 group (37% vs 20%).
Number of relapses was rather low in this group
of patients (2 out of 24 patients). More
aggressive chemotherapy decreased the higher
risk of relapse expected in more advanced
cases. 2. Thiotepa consisting regimen. BuCy4
with or without VP-16 appeared to be less
effective in more advanced acute lymphoblastic
leukemia in children than total body irradiation
(TBI). To increase tumorocidal activity of
chemotherapy (v. Beultzingsloewen et aI., 1995)
Thiotepa (TT) was chosen as a part of
conditioning regimen in high risk patients with
hematological malignancies. TT was primarily
used in our Unit as part of chemotherapy in a
child with medulloblastoma. This treatment
consisted of Bu ( 4 x 150 mg/m2) TT ( 3 x 300
mg/m2).
Acceptable toxicity was observed with good
tumor response. This positive experience
prompted us to use TT according to the protocol
obtained from the Virchow's Klinikum Humboldt
Univesity in Berlin. Altogether 3 patients with
advanced stages of CML and ALL were treated.
Aplastic anemia
STANDARD RISK SEVERE APLASTIC ANE-
MIA.
Cy alone in a dose of 200 mg/kg b.w. was used
as conditioning regimen in 5 children. In all
cases marrow take was documented. Toxicity
of this procedure was neglegible and
consequently no transplant related compli-
cations were seen. This procedure is not
sufficient for patients with multiple transfusions
what we experienced in 45 yrs old adult who
failed to recover after BMT and ultimately died
due to the septic complicaion.
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POOR RISK APLASTIC ANEMIA.
In this group of patients identified by long
standing disease and/or previous blood
transfusions, anti-thymocyte serum was used in
addition to Cy (Storb et aI., 1994). The protocol
is based on Cy ( 4 x 50 mg ) and anti-thymocyte
globulin (ATG, Fresenius: 5 x 5 mg ). ATG
brings risk of CMV reactivation. Ganciclovir may
be used as prophylaxis of Herpes viruses
reactivation. Alternatively, twice weekly repeated
surveillance of CMV antigen in mononuclear
cells can justify the use of Ganciclovir in
prevention of apparent clinical manifestation of
CMV reactivation.
FANCONI ANEMIA ( FA).
This disease is characterised by chromosomal
instability due to theimpairment of free radical
scavenger system. Literature data documented
a high risk of epithelial cancer in patients with FA
receiving irradiation as a part of conditioning
regimen (Deeg et aI., 1996). To avoid this
complication our conditioning protocol is based
on the use of ATG and low dose Cy. Four
children were transplanted so far. They received:
ATG (Fresenius, from 5mg to 15mg per day for
five consecutive days) and Cy ( 4 x 20 mg ). In
all these cases transplantation proved to be
successful with prompt
hematological recovery and without any life-
threatening complications.
ALTERNATIVE TRANSPLANTATIONS AND
HIGH RISK AGVHD PATIENTS.
In alternative haploidentical transplantations two
modalities were chosen. In patients transplanted
from HLA phenotypically donors conditioning
may not differ from that used in standard risk
patients.
In phenotypically identical but genetically
different transplantation ATG together with
BuCy4 was used to increase the level of
immunosuppression. However, this approach
may not be sufficient. In 44 yrs old patient with
CML in accelerated phase grafted from his
mother ( 75 yrs old, who differed in DR4 allelic
subspecificity ) with peripheral blood progenitor
cells a fatal aGvHD appeared at the time of
hematological recovery.
T cell depletion is more effective for aGvHD
prevention. However, removal of T cells from the
graft decreases the efficacy of transplantation in
some hematological malignancies especially in
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CML. Some compromise must be achieved in
these cases between the risk of aGvHD and
benefit of GvL. In haploidentical transplantation
in SCI D case (transplanted from his mother) T
cells were depleted with Campath 1M
monoclonal antibody. This purging, however, did
not prevent progression of preexisting in this
particular case materno-fetal GvHD. In some
situations T cell depletion with monoclonal
antibodies may be too rigorous affecting bone
marrow take. Recently in 46 yrs old male patient
transplanted from his 52 yrs, mUltiparous sister
(HLA and MLC matched) CD2+ cells were
depleted from the graft with the use of an
appriopriate monoclonal antibody and baby
rabbit complement. Hematological reconstitution
was apparent in bone marrow aspirates +10 and
+15 days after transplantation and the patient
reached 500 granulocytes/ul on 21 day after
grafting.
CHEMICAL CONDITIONING vs TBI and C1y.
In our series of patients TBI was not used.
Literature data rather failed to document the
superiority of any of these two procedures with
respect to the event free survival (Blume et al.
1993, Santos 1993). The outcome of the
procedure is affected by the stage of malignant
disease, level of alloimmunization prior to
transplantion, especially in aplastic anemia
cases and level of disparity in alternative and
matched unrelated donor (MUD)
transplantations. There are different toxicities of
TBI and chemical conditioning with rather higher
risk of YOD in the latter treatment protocol and
pneumonitis in TBI patients. In some clinical
situations TBI may be superior. Our own work
suggests that standard SuCy with or without yp-
16 is inferior in comparison to TSI in more
advanced ALL cases (Wachowiak et aI., 1995).
Therefore, in our current approach we favour TT
containing regimen and cranial irradiation prior
to chemical conditioning. The other point of our
concern is liver toxicity in HBY and/or HCY
positive cases. Unfortunatelly a proportion of
patients referred to our unit for
allotransplantation were infected with HBY or
HCY. More aggressive chemical conditioning is
associated with a higher incidence of hepatic
toxicity (Nevill et al. 1991). Patients with history
of viral hepatitis can benefit from TBI more than
those not affected by hepatitis viruses.
Drawbacks of not using TSI seem to be partly
compensated by rather low incidence of CMY
pneumonitis which was seen only in one out of
64 transplanted patients. Chemical conditioning
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and TBI "should be used accordingly to the
clinical needs (Ringden et al. 1994) and this is
taken into consideration in planning further
development of alioBM/Blood transplantations in
our institution.
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